QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships

About this update from Qiagen N.v.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":242,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/029fef26afed91513d9426549e655db4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Pejskv6QelzaIcOE1Ta5DA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM1NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/029fef26afed91513d9426549e655db4","width":242,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Two new partnerships enhance QIAGEN’s capabilities to support pharma partner clinical trials with significant expansion of MRD capabilities – especially using QIAcuity digital PCR","length":179,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":179,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Tracer Biotechnologies partnership to develop blood-based minimal residual disease (MRD) tests on QIAcuity digital PCR systems for solid cancer tumors","length":150,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":150,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Collaboration with Foresight Diagnostics aims to develop a kit version of its CLARITY™ NGS assay for use in lymphoma","length":116,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":116,"olType":false},{"type":"text","content":"VENLO, Netherlands, June 02, 2025--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual disease (MRD) testing in clinical trials to support pharma co-development projects for companion diagnostics. The new collaborations with Tracer Biotechnologies and Foresight Diagnostics expand QIAGEN’s reach in MRD testing and cover solid tumors and hematological cancers.","length":515,"tagName":"p"},{"type":"text","content":"Minimal residual disease (MRD) testing is becoming a cornerstone of oncology by enabling early detection of cancer recurrence and guiding timely adjustments to therapy from a blood sample. These new partnerships support the growing demand for decentralized, non-invasive tools that advance precision medicine and help deliver more personalized ...

More updates from Qiagen N.v.